JP2015521639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521639A5 JP2015521639A5 JP2015518999A JP2015518999A JP2015521639A5 JP 2015521639 A5 JP2015521639 A5 JP 2015521639A5 JP 2015518999 A JP2015518999 A JP 2015518999A JP 2015518999 A JP2015518999 A JP 2015518999A JP 2015521639 A5 JP2015521639 A5 JP 2015521639A5
- Authority
- JP
- Japan
- Prior art keywords
- ingenol
- acetonide
- pharmaceutically acceptable
- pyridyl
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, hydroxyl Chemical group 0.000 claims 62
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000002148 esters Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 6
- 239000002537 cosmetic Substances 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 208000009621 actinic keratosis Diseases 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010051999 Anogenital dysplasia Diseases 0.000 claims 3
- 206010059313 Anogenital warts Diseases 0.000 claims 3
- 206010008263 Cervical dysplasia Diseases 0.000 claims 3
- 208000000907 Condylomata Acuminata Diseases 0.000 claims 3
- 206010058314 Dysplasia Diseases 0.000 claims 3
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims 3
- 206010041303 Solar dermatitis Diseases 0.000 claims 3
- 208000000260 Warts Diseases 0.000 claims 3
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 claims 3
- 201000004201 anogenital venereal wart Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 206010020718 hyperplasia Diseases 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 230000009826 neoplastic cell growth Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 201000003385 seborrheic keratosis Diseases 0.000 claims 3
- 201000010153 skin papilloma Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 210000003905 vulva Anatomy 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000006001 difluoroethyl group Chemical group 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664398P | 2012-06-26 | 2012-06-26 | |
| US61/664,398 | 2012-06-26 | ||
| US201361763206P | 2013-02-11 | 2013-02-11 | |
| US61/763,206 | 2013-02-11 | ||
| PCT/EP2013/062995 WO2014001215A2 (en) | 2012-06-26 | 2013-06-21 | 3-o-heteroaryl-ingenol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521639A JP2015521639A (ja) | 2015-07-30 |
| JP2015521639A5 true JP2015521639A5 (enExample) | 2016-08-04 |
| JP6216781B2 JP6216781B2 (ja) | 2017-10-18 |
Family
ID=48874993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518999A Expired - Fee Related JP6216781B2 (ja) | 2012-06-26 | 2013-06-21 | ３−ｏ−ヘテロアリール−インゲノール |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9422309B2 (enExample) |
| EP (1) | EP2864290B1 (enExample) |
| JP (1) | JP6216781B2 (enExample) |
| KR (1) | KR20150024928A (enExample) |
| CN (1) | CN104411685B (enExample) |
| AU (1) | AU2013283511B2 (enExample) |
| BR (1) | BR112014032244A2 (enExample) |
| CA (1) | CA2875461A1 (enExample) |
| DK (1) | DK2864290T3 (enExample) |
| ES (1) | ES2640612T3 (enExample) |
| IL (1) | IL235925A0 (enExample) |
| IN (1) | IN2014DN11023A (enExample) |
| MX (1) | MX2014015497A (enExample) |
| MY (1) | MY169215A (enExample) |
| NZ (1) | NZ702835A (enExample) |
| PL (1) | PL2864290T3 (enExample) |
| PT (1) | PT2864290T (enExample) |
| RU (1) | RU2015102095A (enExample) |
| SG (1) | SG11201408016XA (enExample) |
| WO (1) | WO2014001215A2 (enExample) |
| ZA (1) | ZA201409022B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3060304A1 (en) | 2013-10-25 | 2016-08-31 | Leo Laboratories Limited | A method for topically treating actinic keratosis with ingenol 3-(3,5-diethylisoxazole-4-carboxylate) |
| WO2016191835A1 (pt) * | 2015-06-03 | 2016-12-08 | Amazônia Fitomedicamentos Ltda. | Método de preparação de ingenol-5,20-acetonida, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0] heptano-2-carbaldeído, método de preparação do composto 2,2-dimetil-4-etinil-5 -trifenilfosforanilideno-1,3-dioxano e composto intermediário |
| US12502369B2 (en) | 2015-11-11 | 2025-12-23 | K-Gen, Inc. | Methods of cancer treatment |
| WO2017089300A1 (en) * | 2015-11-27 | 2017-06-01 | Leo Laboratories Limited | 3-alkylamido-3-deoxy-ingenols |
| WO2017130156A1 (en) | 2016-01-27 | 2017-08-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Ingenol analogs, pharmaceutical compositions and methods of use thereof |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2902506A1 (de) | 1979-01-23 | 1980-07-24 | Deutsches Krebsforsch | Verwendung von nicht oder nur gering irritierenden und/oder promovierenden diterpenalkoholen und von derivaten davon als antineoplastische mittel |
| AUPO864097A0 (en) | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
| WO2006063382A1 (en) * | 2004-12-13 | 2006-06-22 | Peplin Research Pty Ltd | Treatment of solid cancers |
| CN101360506A (zh) * | 2005-11-25 | 2009-02-04 | 派普林研究股份有限公司 | 创伤愈合的方法 |
| GB0525680D0 (en) | 2005-12-16 | 2006-01-25 | Peplin Ltd | Therapeutic compositions |
| CA2685473C (en) * | 2007-04-30 | 2015-09-01 | Peplin Research Pty Ltd | Treatment of virally induced lesions |
| JP2010526824A (ja) | 2007-05-11 | 2010-08-05 | ソネボーン インコーポレイテッド | シリコーン類似の特性を有するワセリン |
| JP5911508B2 (ja) | 2010-12-22 | 2016-04-27 | レオ・ラボラトリーズ・リミテッドＬｅｏ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ | ３−アシル−インゲノールｉｉ |
| EP2655311A1 (en) | 2010-12-22 | 2013-10-30 | Leo Laboratories Limited | Ingenol-3-acylates i |
| TWI548616B (zh) | 2010-12-22 | 2016-09-11 | 理奧實驗有限公司 | 巨大戟萜醇－３－醯化物iii及巨大戟萜醇－３－胺基甲酸酯化物 |
-
2013
- 2013-06-21 US US14/409,374 patent/US9422309B2/en not_active Expired - Fee Related
- 2013-06-21 WO PCT/EP2013/062995 patent/WO2014001215A2/en not_active Ceased
- 2013-06-21 CN CN201380033726.9A patent/CN104411685B/zh not_active Expired - Fee Related
- 2013-06-21 DK DK13741681.4T patent/DK2864290T3/en active
- 2013-06-21 MX MX2014015497A patent/MX2014015497A/es unknown
- 2013-06-21 CA CA2875461A patent/CA2875461A1/en not_active Abandoned
- 2013-06-21 KR KR1020157002108A patent/KR20150024928A/ko not_active Withdrawn
- 2013-06-21 SG SG11201408016XA patent/SG11201408016XA/en unknown
- 2013-06-21 PL PL13741681T patent/PL2864290T3/pl unknown
- 2013-06-21 IN IN11023DEN2014 patent/IN2014DN11023A/en unknown
- 2013-06-21 BR BR112014032244A patent/BR112014032244A2/pt not_active IP Right Cessation
- 2013-06-21 JP JP2015518999A patent/JP6216781B2/ja not_active Expired - Fee Related
- 2013-06-21 PT PT137416814T patent/PT2864290T/pt unknown
- 2013-06-21 EP EP13741681.4A patent/EP2864290B1/en not_active Not-in-force
- 2013-06-21 ES ES13741681.4T patent/ES2640612T3/es active Active
- 2013-06-21 AU AU2013283511A patent/AU2013283511B2/en not_active Ceased
- 2013-06-21 MY MYPI2014703954A patent/MY169215A/en unknown
- 2013-06-21 RU RU2015102095A patent/RU2015102095A/ru not_active Application Discontinuation
- 2013-06-21 NZ NZ702835A patent/NZ702835A/en not_active IP Right Cessation
-
2014
- 2014-11-26 IL IL235925A patent/IL235925A0/en unknown
- 2014-12-09 ZA ZA2014/09022A patent/ZA201409022B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7181967B2 (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| ES2987744T3 (es) | Inhibidores de calicreína plasmática y usos de los mismos | |
| ES2908042T3 (es) | Heteroarilos y usos de los mismos | |
| JP5911638B2 (ja) | ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用 | |
| ES2660914T3 (es) | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD | |
| TW200914458A (en) | Inhibitors of protein tyrosine kinase activity | |
| CA3117850A1 (en) | Ret inhibitors, pharmaceutical compositions and uses thereof | |
| BR112019012957A2 (pt) | derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1 | |
| ES2706525T3 (es) | Derivados de piridinilquinolinona como inhibidores de isocitrato deshidrogenasa mutante | |
| ES2828503T3 (es) | Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos | |
| ES2824801T3 (es) | Sal de compuesto heterocíclico sustituido con halógeno | |
| AU2009206775A1 (en) | Protein kinase inhibitors and use thereof | |
| CN106478500A (zh) | 羧酸取代的（杂）芳环类衍生物及其制备方法和用途 | |
| JP2018501315A5 (enExample) | ||
| RU2015102095A (ru) | 3-о-гетероарилингенол | |
| US20210355107A1 (en) | Multi-substituted pyridone derivatives and medical use thereof | |
| TWI508968B (zh) | 用於治療呼吸道融合性病毒感染的化合物 | |
| TW202003487A (zh) | 經取代的２，２＇—聯嘧啶基化合物、其類似物及其使用方法 | |
| CN105523955A (zh) | 化合物及其在制备药物中的用途 | |
| JP2025529797A (ja) | 複素環ｒｂｍ３９モジュレーター | |
| JP2018522909A (ja) | ヒト免疫不全ウイルス複製の阻害剤としての５−（ｎ−縮合三環式アリールテトラヒドロイソキノリン−６−イル）ピリジン−３−イル酢酸誘導体 | |
| TWI804295B (zh) | 作為甲硫胺酸腺苷轉移酶抑制劑的化合物、其製備方法及應用 | |
| CN102858769A (zh) | 吡唑并吡啶激酶抑制剂 | |
| WO2023134713A1 (zh) | 氮杂并环衍生物、其药物组合物及其用途 | |
| CN118556044A (zh) | 稠杂环类化合物、其制备方法及其在医药上的应用 |